The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies

The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

“…Although with some criticisms related to the different European health systems, the culture on the agnostic therapies is growing overtime (Horgan et al, 2021;Knepper et al, 2017;Russo et al, 2021b). A critical issue to be addressed is the real sustainability of this mutational model and, consequently, of the MTBs (Fig.…”

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

“…It has been shown that both germinal and somatic BRCA PVs represent predictive biomarkers of greater sensitivity to treatment with inhibitors of the PARP enzyme, which is involved in the repair of damaged single-filament DNA. 9 , 10 The efficacy of PARP inhibitors as a therapeutic option in tumors of patients carrying a BRCA PV is considered to occur mainly through a mechanism of ‘synthetic lethality’ in the presence of a concomitant loss of function of double-stranded DNA repair mechanisms by homologous recombination, in which BRCA1/2 proteins play an essential role. 10 , 11 …”

“… 9 , 10 The efficacy of PARP inhibitors as a therapeutic option in tumors of patients carrying a BRCA PV is considered to occur mainly through a mechanism of ‘synthetic lethality’ in the presence of a concomitant loss of function of double-stranded DNA repair mechanisms by homologous recombination, in which BRCA1/2 proteins play an essential role. 10 , 11 …”

The molecular tumor board: a tool for the governance of precision oncology in the real world

“…Economic sustainability of genomic tests, access to drugs or clinical trials according to the MTB recommendation, and expanded use of existing anticancer drugs are required in order for MTBs to become a useful tool for the governance of precision oncology. 4,10 This is an ongoing process in which the establishment of MTBs is the first step. Integrated scientific and clinical skills must follow the complex and rapid evolution of cancer genetics and the availability of novel or investigational anticancer therapies.…”